JACS AuBiochemistryPeer-reviewed journal article
Paralogue-selective degradation of the lysine acetyltransferase EP300
Xuemin CheniD, McKenna C. CrawfordiD, Ying XiongiD, Anver Basha ShaikiD, Kiall F. SuazoiD, Ludwig G. BaueriD, Manini S. Penikalapati, Joycelyn H. Williams, K. HuberiD, Thorkell Andressen, Rolf E. SwensoniD, Jordan L. MeieriD
Abstract
The transcriptional coactivators EP300 and CREBBP are critical regulators of gene expression that share high sequence identity but exhibit non-redundant functions in basal and pathological contexts. Here, we report the development of a bifunctional small molecule, MC-1, capable of selectively degrading EP300 over CREBBP. Using a potent aminopyridine-based inhibitor of the EP300/CREBBP catalytic domain in combination with a VHL ligand, we demonstrate that MC-1 preferentially degrades EP300 in a proteasome-dependent manner. Mechanistic studies reveal that selective degradation cannot be predicted solely by target engagement or ternary complex formation, suggesting additional factors govern paralogue-specific degradation. MC-1 inhibits cell proliferation in a subset of cancer cell lines and provides a new tool to investigate the non-catalytic functions of EP300 and CREBBP. Our findings expand the repertoire of EP300/CREBBP-targeting chemical probes and offer insights into the determinants of selective degradation of highly homologous proteins.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 12
- FWCI
- 1.38
- Field percentile
- top 20%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparative analysis of drug-like EP300/CREBBP acetyltransferase inhibitors
M. C. Crawford, D. R. Tripu, … J. L. Meier·bioRxiv·May 15, 2023
- A Strategy to Assess the Cellular Activity of E3 Ligases against Neo-Substrates using Electrophilic Probes
Benika J. Pinch, Dennis L. Buckley, … Claudio R. Thoma·Cell chemical biologyPeer-reviewed·Sep 8, 2021
- A CRISPR activation screen identifies FBXO22 as an E3 ligase supporting targeted protein degradation
A. A. Basu, C. Zhang, … X. Zhang·bioRxiv·Sep 15, 2023
- Hijacking Methyl Reader proteins for Nuclear-Specific Protein Degradation
D. A. Nalawansha, K. Li, … C. M. Crews·bioRxiv·Jan 24, 2022
- ByeTAC: Bypassing an E3 Ligase for Targeted Protein Degradation
E. M. Ali, C. Loy, D. J. Trader·bioRxiv·Jan 20, 2024
- Mechanism of degrader-targeted protein ubiquitinability
C. Crowe, M. Nakasone, … A. Ciulli·bioRxiv·Feb 5, 2024